Clinical Trials Logo

Arrhythmia clinical trials

View clinical trials related to Arrhythmia.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04472520 Withdrawn - Arrhythmia Clinical Trials

Use of AliveCor ECG Monitoring to Replicate ECG Lead Recording

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The researchers are trying to determine whether the Alivecor device can simulate other electrocardiogram (ECG) leads to record electrical activity.

NCT ID: NCT04279665 Withdrawn - Arrhythmia Clinical Trials

Virtual Reality to Reduce Intra-procedural Anxiety and Sedation Needs During Procedures

Start date: June 20, 2020
Phase: N/A
Study type: Interventional

Researchers are assessing whether use of a virtual reality experience, used during the procedure, can reduce anxiety and improve satisfaction related to the procedure, especially when no or little sedation is being used.

NCT ID: NCT02758002 Withdrawn - Atrial Fibrillation Clinical Trials

Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms

TRANS AF
Start date: January 28, 2016
Phase: N/A
Study type: Interventional

There is growing awareness of the importance of electrical rotors to the maintenance of atrial fibrillation (AF). Recent work in our laboratory has found that AF evolves over time, from rapid, focal activation, next to transitional rotors, and finally to stable, long duration rotors, whose locations are frequently separate from the transitional rotor sites. This project will test the hypothesis that mapping and ablation of the transitional rotors sites may prevent atrial fibrillation from progressing to sustained atrial fibrillation, and therefore increase the AF initiation threshold. The investigators will test this hypothesis during clinically-indicated electrophysiology study prior to ablation of symptomatic AF.

NCT ID: NCT02599857 Withdrawn - Heart Failure Clinical Trials

The Effects of a CONCOR Smartphone Application

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Life expectancy of children with congenital heart disease (CHD) has increased dramatically during the past years, due to the successes of cardiac surgery. Nearly all of these children with CHD can be operated at young age and more than 90% reach adulthood. However, many adults with CHD are life-long affected by cardiac events, particularly arrhythmias and heart failure, putting them at risk of premature death. These events have a large impact on quality of life of patients and their families and merit life-long hospital visits in a medical center specialized in adult CHD. Especially for adults with CHD patient care with a smartphone is suited because of their young age and chronic condition. So far, data are lacking on smartphone interventions in patients with CHD.

NCT ID: NCT01082601 Withdrawn - Atrial Fibrillation Clinical Trials

Catheter Ablation for Atrial Fibrillation and Heart Failure

Start date: April 2010
Phase: N/A
Study type: Observational

To compare heart function, symptoms, exercise capacity and quality of life in patients with Congestive Heart Failure (CHF) and Atrial Fibrillation (AF)before and after catheter ablation. Hypothesis: Restoration and maintenance of sinus rhythm by catheter ablation, without the use of antiarrhythmic drugs, in AF and CHF improves heart failure status.

NCT ID: NCT00789165 Withdrawn - Arrhythmia Clinical Trials

Empiric Quinidine for Asymptomatic Brugada Syndrome

Start date: December 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine if quinidine therapy (not guided by the results of electrophysiologic studies) will reduce the long-term risk of arrhythmic events in asymptomatic Brugada Syndrome.

NCT ID: NCT00507390 Withdrawn - Arrhythmia Clinical Trials

Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia

Start date: January 2007
Phase: Phase 4
Study type: Interventional

This is a hypothesis testing study, the hypothesis being that dietary supplements of n-PUFAs concentrates are anti-arrhythmic in ventricular arrhythmic substrates. Study Aims: To investigate whether dietary supplements of n-3 polyunsaturated fatty acid concentrates (2g PUFAs/day, Omacor) reduces MTWA (a surrogate endpoint for ventricular arrhythmia substrate) in patients with ICDs for malignant ventricular arrhythmias.